Core Viewpoint - Livzon Pharmaceutical Group Inc. has announced that its subsidiary, Zhuhai Livzon Monoclonal Antibody Biotechnology Co., Ltd., in collaboration with Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., has had its product, Lakanqita Monoclonal Antibody Injection, included in the priority review list by the National Medical Products Administration (NMPA) of China, marking a significant step towards expedited approval for market launch [1] Group 1 - The product Lakanqita Monoclonal Antibody Injection was officially included in the priority review list after the public notice period ended [1] - The inclusion in the priority review list indicates that the product will undergo expedited approval procedures for drug market licensing [1]
丽珠医药(01513)：莱康奇塔单抗注射液被纳入优先审评审批程序